tbuckley/cabot-search huggingface dataset:
Tardive dyskinesia and substrates of energy metabolism in CSF
Authors: D C Goff, G Tsai, M F Beal, J T Coyle
Journal: American Journal of Psychiatry (1995)

This study was undertaken to assess the relationships among CSF concentrations of substrates of mitochondrial energy metabolism, neuroleptic medication, and neurological side effects.CSF was obtained from 25 patients with schizophrenia; seven were unmedicated and 11 had tardive dyskinesia. CSF concentrations of four substrates of mitochondrial energy metabolism (Krebs cycle)--alanine, aspartate, lactate, and pyruvate--were determined. Tardive dyskinesia was measured with the Abnormal Involuntary Movement Scale (AIMS), and parkinsonism was measured with the Simpson-Angus Rating Scale.CSF concentrations of alanine were significantly elevated in the medicated patients when tardive dyskinesia status was controlled for. CSF aspartate concentrations were significantly elevated in patients with tardive dyskinesia when medication status was controlled for and were significantly correlated with total scores on the AIMS.These results are consistent with a model linking neuroleptic-induced neurological side effects with impairment of mitochondrial energy metabolism, possibly mediated by inhibition of complex 1 of the electron transport chain.
Dealing with Lung Cancer TNM Classification
Authors: Jacques Giron, Alexis Lacout, Pierre Yves Marcy
Journal: Journal of Thoracic Oncology (2016)

The tumor, node, and metastasis (TNM) classification aims at stratifying groups of patients with a similar prognosis to plan the appropriate therapeutic options. The TNM classification is regularly updated owing to the evolving science. For example, it is noteworthy that neoplastic pleural effusion, which was previously staged as T4M0 according to the fifth (1997) and sixth editions (2002) of the TNM classification,1 is henceforth considered a metastatic stage (M1a) according to the seventh (2007) and newest (eighth) TNM classification (2016).
Should player fatigue be the focus of injury prevention strategies for international rugby sevens tournaments?
Authors: Colin W Fuller, Aileen E Taylor, Martin Raftery
Journal: British Journal of Sports Medicine (2016)

To assess the incidence, severity and nature of injuries, to determine risk factors for injury and to identify potential injury prevention strategies in men's international Rugby-7s tournaments.A prospective cohort study.Players from core teams competing in matches at 6 Sevens World Series from 2008/2009 to 2014/2015.The incidence of injury across all Series was 108.3 injuries/1000 player-match-hours (backs: 121.0; forwards: 91.5) with a mean severity of 44.2 days (backs: 46.1; forwards: 40.9) and a median severity of 28 days (backs: 29; forwards: 26). The proportion of injuries sustained in the second half was significantly higher (60%; p<0.001) than the first half of matches and the proportion increased from match to match and day to day in a tournament. The knee (17.4%), ankle (15.9%) and posterior thigh (13.2%) were the most common injury locations for backs and the knee (18.5%), head/face (17.3%) and shoulder/clavicle (13.0%) for forwards. The four most common injuries across all players were knee ligament (13.0%), ankle ligament (12.8%), concussion (10.4%) and posterior thigh muscle strains (9.8%).The incidence of injury in Rugby-7s suggests that teams require squads of around 20 players for a Sevens World Series. The higher incidence of injury in the second half of matches is probably the result of player fatigue; therefore, injury prevention strategies for teams and the Governing Body should address this issue. The results presented support the World Rugby trial allowing 'rolling substitutes' during Sevens World Series matches, as this approach may help to mitigate the effects of player fatigue during the second half of matches.
Abstract A21: Ovarian tumor cells' adhesion and cell signaling pathways are regulated by ARID3B.
Authors: Alexander S. Bobbs, William Morgan Hallas, Karen D. Cowden Dahl.
Journal: Clinical Cancer Research (2016)

Abstract Patients with ovarian cancer are often diagnosed with late-stage metastatic cancer resulting in poor survival rates. To improve both diagnostics and therapeutics, we need to increase our understanding of the genetic programming that leads to metastatic ovarian cancer. We found that the DNA-binding protein AT-Rich Interactive Domain 3B (ARID3B) is over-expressed in ovarian cancer. Nuclear expression of ARID3B correlates with relapse following chemotherapy. Furthermore, ARID3B increases tumor growth in a xenograft model of ovarian cancer. We hypothesize that ARID3B modulates adhesion and survival by regulating genes in the Wnt and TNF pathways. We identified and validated direct target genes of ARID3B by chromatin immunoprecipitation (ChIP), and characterized the binding site for ARID3B. ARID3B regulates target genes in the Wnt signaling pathway including Wnt5A, FZD5, and APC. ARID3B increases adhesion to extra-cellular matrix at least in part through regulation of FZD5. In addition to regulation of adhesion through Wnt signaling, we found that decreased ARID3B leads to a reduction in fibronectin and vitronectin adhesion. ARID3B also seems to play a role in regulating cell death and survival. We found that ARID3B regulates genes in the TNF and TRAIL signaling pathways. In particular, TNF, TNFR2, and TRAIL are ARID3B regulated genes. We are investigating the impact of TNF and TRAIL regulation on cell death and survival. This study directly demonstrates that ARID3B is a transcription factor that regulates target expression of key components of the Wnt and TNF signaling pathways. Citation Format: Alexander S. Bobbs, William Morgan Hallas, Karen D. Cowden Dahl. Ovarian tumor cells' adhesion and cell signaling pathways are regulated by ARID3B. [abstract]. In: Proceedings of the AACR Special Conference on Advances in Ovarian Cancer Research: Exploiting Vulnerabilities; Oct 17-20, 2015; Orlando, FL. Philadelphia (PA): AACR; Clin Cancer Res 2016;22(2 Suppl):Abstract nr A21.
Abstract B33: The oligoclonal antibody MM-151 overcomes acquired resistance to cetuximab and panitumumab in colorectal cancer cells harboring EGFR extracellular domain mutations
Authors: Sabrina Arena, Giulia Siravegna, Benedetta Mussolin, Jeffrey D. Kearns, Beni B. Wolf, Sandra Misale, Luca Lazzari, Andrea Bertotti, Livio Trusolino, Alex Adjei, Clara Montagut, Federica Di Nicolantonio, Rachel Nering, Alberto Bardelli
Journal: Cancer Research (2016)

Abstract The anti-EGFR antibodies cetuximab and panitumumab are used to treat ‘RAS’ wild type colorectal cancers (CRCs), but their efficacy is limited by development of drug resistance. At relapse, approximately 20% of tumors carry EGFR extracellular domain (ECD) mutations (S492R, R451C, S464L, G465R, G465E, K467T, I491M) that impair antibody binding. We find that these EGFR genetic variants are effectively targeted by the oligoclonal anti-EGFR antibody MM-151. Both EGFR mediated signaling and proliferation of colorectal cancer (CRC) cells carrying EGFR ECD mutations are impaired by MM-151. Notably, EGFR extracellular domain mutations, which are found in circulating free tumor DNA (ctDNA) of CRC patients who relapsed upon anti-EGFR antibodies treatment, decline during MM-151 therapy. In conclusion, MM-151 based therapy may be valuable for the treatment of secondary resistance to cetuximab and panitumumab driven by EGFR ECD mutations. Further prospective clinical evaluation is warranted. Citation Format: Sabrina Arena, Giulia Siravegna, Benedetta Mussolin, Jeffrey D. Kearns, Beni B. Wolf, Sandra Misale, Luca Lazzari, Andrea Bertotti, Livio Trusolino, Alex Adjei, Clara Montagut, Federica Di Nicolantonio, Rachel Nering, Alberto Bardelli. The oligoclonal antibody MM-151 overcomes acquired resistance to cetuximab and panitumumab in colorectal cancer cells harboring EGFR extracellular domain mutations. [abstract]. In: Proceedings of the Fourth AACR International Conference on Frontiers in Basic Cancer Research; 2015 Oct 23-26; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2016;76(3 Suppl):Abstract nr B33.
Is dying being worked to death?
Authors: R J Cohen
Journal: American Journal of Psychiatry (1976)

In recent years there has been a dramatic increase in the number of books and articles on death and dying. The ambivalence of some writers regarding the value of this proliferation of papers led the author to review and evaluate this literature; he found seven overlapping categories of death-related literature that were of both theoretical and practical value. He briefly explores possible reasons for the rise in this subject's popularity.
Motoric lateralization in schizophrenic males
Authors: H A Nasrallah, K Keelor, C Van Schroeder, M M Whitters
Journal: American Journal of Psychiatry (1981)

Over an 8-month period 84 male patients with schizophrenia were tested for handedness. The authors' data suggest that there is an increased frequency of left-handedness, as well as mixed-handedness, among schizophrenic patients.
Early Systematic Palliative Care in Metastatic Cancer Patients (Pts) in an Italian Oncology Unit (Ou): Impact on Quality of Care, Medical Service Use and Patient Quality of Life (Qol)
Authors: I. Pavese, M. Di Palma, F. Satta, E. Burattini, G. Coiro, V. Zoffoli, F. Todi
Journal: Annals of Oncology (2014)
LONDON PANEL COMMITTEE AND THE SUPPLY OF LOCUMTENENTS
Authors: J. J. Scanlan
Journal: BMJ (1914)

Around 1.4% of the UK population have gout, the prevalence of which increases with age to around 3% in women and 7% in men aged over 75 years.1–3 Acute gout is intensely painful and can reduce patients’ quality of life.2<sup>,</sup>3 It occurs when the serum uric acid concentration (SUA) rises (hyperuricaemia) and persists above the solubility threshold of monosodium urate (400μmol/L [6.8mg/dL]), leading to urate crystal formation that causes arthritis, gouty tophi (nodules) in subcutaneous tissues and renal calculi.3–5 The mainstay of treatment for chronic gout is allopurinol, which inhibits xanthine oxidase (an enzyme involved in the production of uric acid in the body). However, this drug has to be stopped in a minority of patients due to rashes or hypersensitivity.6 ▼Febuxostat (Adenuric – Menarini/Ipsen), another xanthine oxidase inhibitor, is a newly licensed treatment for chronic hyperuricaemia in conditions where urate deposition has occurred.7 Here we consider its place for patients with gout.
Abstract IA25: Identifying and profiling tumor specific T cells using mass cytometry and highly multiplexed peptide-MHC tetramer staining
Authors: Evan W. Newell
Journal: Cancer Research (2016)

Abstract Antigen specific T cells are critical initiators and orchestrators of the adaptive immune response. To better understand how T cells participate (appropriately or inappropriately) in the immune response to cancer, more meaningful categorizations of these cells are needed. For this purpose, a very large number of cellular parameters can be considered. Focusing on human CD8+ T cells, the utility of high dimensional mass cytometry (i.e., Cytometry by Time-Of-Flight, CyTOF) analysis will be discussed. By this approach, T cells can be probed with unprecedented detail by simultaneously evaluating surface marker expression, functional capacity and antigen-specificity. For antigen-specificity, this analysis can be performed in conjunction with a highly multiplexed method based on peptide-MHC tetramers, which allows simultaneous assessment of &amp;gt;500 different antigen specificities in a single sample. To visualize and understand the diversity of these cells, several computational data analysis approaches are being used. Application of these approaches to identify and phenotypically profile various cancer specific T cells in humans as well as in mouse models will be described. In addition to the possibility of finding novel therapeutic targets, a long-term goal of this work is to discover more accurate biomarkers of clinical outcomes (e.g., responsiveness to immunotherapy) based on the high-dimensional characteristics of antigen-specific T cells. Citation Format: Evan W. Newell. Identifying and profiling tumor specific T cells using mass cytometry and highly multiplexed peptide-MHC tetramer staining. [abstract]. In: Proceedings of the Fourth AACR International Conference on Frontiers in Basic Cancer Research; 2015 Oct 23-26; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2016;76(3 Suppl):Abstract nr IA25.
Variability of hormonal responses to a series of neuroendocrine challenges in depressed patients
Authors: A Winokur, J Amsterdam, S Caroff, P J Snyder, D Brunswick
Journal: American Journal of Psychiatry (1982)

Abnormalities of hormonal responses to a number of neuroendocrine challenges have been reported in depressed patients. The authors used a series of four neuroendocrine challenges-thyrotropin-releasing hormone (TRH) and gonadotropin-releasing hormone (GnRH) stimulation, insulin tolerance test (ITT), and overnight dexamethasone suppression test (DST)-and examined eight hormonal responses in 24 healthy subjects and 26 patients with primary unipolar affective disorder. Seven control subjects (29.2%) and 25 depressed patients (96.2%) had at least one abnormal response, and 15 depressed patients (57.7%) had two or mor abnormal responses. These findings suggest that depressed patients show variability in hormonal response across a number of neuroendocrine axes. No consistent patterns of abnormality of hormonal response were observed.
Seasonality and affective illness
Authors: T A Wehr, N E Rosenthal
Journal: American Journal of Psychiatry (1989)

The authors review what has been learned about the causes, symptoms, and treatments of seasonal affective disorder and discuss its relevance to affective illness in general. They point out that seasonal and environmental influences on depression have been themes in writings on affective illness for more than 2,000 years and that there has been a resurgence of interest during the past decade. There appear to be two primary, opposite seasonal patterns of annual depression--winter depression and summer depression--with opposite vegetative symptoms. Seasonal affective disorder is not uncommon. It is important to identify patients with winter depression because they respond to a specific treatment, phototherapy.
Abstract P5-02-01: Diagnosis of pathological complete response by vacuum-assisted minimal invasive biopsy after neoadjuvant chemotherapy in breast cancer - Results from a prospective pilot study
Authors: A Hennigs, J Heil
Journal: Cancer Research (2016)

Abstract Purpose: To explore the ability of vacuum-assisted-biopsy (VAB) to diagnose pathological complete response (pCR) or residual tumor in breast cancer patients after neoadjuvant chemotherapy (NACT). Patients and methods: 50 patients (22 with clinical / imaging complete response 28 with clinical / imaging residual tumor) were included in this review-board approved prospective pilot study between 08/14 and 02/15. Vacuum-assisted-biopsy (VAB) was performed after NACT and before surgery. Negative predictive values (NPV) and false-negative-rates (FNR) to predict a pCR in surgical specimen (=diagnose pCR through VAB) were the main outcome measures. Results: The cohort (n=50) consisted of 15 (30%) triple negative (TNBC), 13 (26%) HER2 positive (HER2+) and 22 (44%) hormone receptor positive / HER2 negative (HR+/HER2-) cancers. pCR in surgical specimen was diagnosed in 23 (46%) cases of the whole cohort. The NPV of the VAB diagnosis of pCR was 94.4% (95% CI: [0.84; 1.00]). The FNR was 3.7% (95% CI: [0; 0.12]) and specificity 73.9% (95% CI: [0.54; 0.94]). Taking only those biopsies into account that pathology confirmed to be representative of the (former) tumor region, improved the outcome of VAB to a specificity of 100% while the NPV (94.4% (95% CI: [0.84; 1.00]) and the FNR (4.8% (95% CI: [0.00; 0.15]) stayed the same. Conclusion: Overall accuracy of VAB diagnosis of pCR questions the necessity of surgical intervention to diagnose a pCR. A confirmative, multi-center, intra-individually-controlled clinical trial including patients with clinical complete, near complete or partial response to NACT to validate the above mentioned results is warranted. Citation Format: Hennigs A, Heil J. Diagnosis of pathological complete response by vacuum-assisted minimal invasive biopsy after neoadjuvant chemotherapy in breast cancer - Results from a prospective pilot study. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P5-02-01.
Abstract B76: Involuntary weight loss is an independent prognostic factor for overall survival and predicts better response to chemotherapy in high-grade serous ovarian cancer patients.
Authors: J. Jan Sznurkowski, Maciej Pawlowski, Pawel Kabata
Journal: Clinical Cancer Research (2016)

Abstract High-grade serous ovarian cancer (HGSOC) is the most common and very aggressive histological type of this neoplasm. Most of the patients require platinum-based chemotherapy following primary surgical treatment. Aim: to assess the prognostic value of involuntary weight loss between surgery and first cycle of chemotherapy. Material and methods: Out of 73 patients surgically treated for HGSOC, 64 received adjuvant chemotherapy. Prognostic value of several clinico-pathological features was assessed, including change of body weight between the day of primary debulking surgery and 1st cycle of chemotherapy. Survival analyses included the Kaplan–Meier method, log-rank test and Cox proportional hazards model. Results: The median follow-up was 47.25 months (range 17–79 months). Median change of body weight in the group of 64 patients who received chemotherapy was -3.5 kg (range from -33kg to +5kg). Higher weight loss values (median -5 kg, range: -1 to -33 kg) were observed in platinum-resistant patients (n=21) compared to platinum-sensitive ones (n=43) (median -3.5 kg, range: -5 to -14 kg) (p= 0.03). Weight loss between primary surgery and first cycle of chemotherapy was found to be independent prognostic factor for decreased OS (HR=3.8, CI 95%= 1.15-12.53, p=0.0285) and PFS (HR= 3.07; CI 95%= 1.28-7.38; p= 0.0123). Conclusions: Prevention of weight loss and nutritional wasting in HGSOC patients planned for adjuvant chemotherapy might improve results of treatment. Further prospective trials on nutrition of this group of patients are needed. Citation Format: J. Jan Sznurkowski, Maciej Pawlowski, Pawel Kabata. Involuntary weight loss is an independent prognostic factor for overall survival and predicts better response to chemotherapy in high-grade serous ovarian cancer patients. [abstract]. In: Proceedings of the AACR Special Conference on Advances in Ovarian Cancer Research: Exploiting Vulnerabilities; Oct 17-20, 2015; Orlando, FL. Philadelphia (PA): AACR; Clin Cancer Res 2016;22(2 Suppl):Abstract nr B76.
Single Umbilical Artery: Incidence, Clinical Significance, and Relation to Autosomal Trisomy
Authors: E F LENOSKI, H MEDOVY
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Telomeres on Steroids — Turning Back the Mitotic Clock?
Authors: Peter M Lansdorp
Journal: New England Journal of Medicine (2016)

In a study reported in this issue of the Journal, Townsley et al. found that patients with diseases that are thought to result from defective telomere maintenance benefit from treatment with androgenic anabolic steroids.1 All 12 of the patients they examined had normalization of their leukocyte telomere attrition rate,2 and 11 of the 12 had evidence of telomere elongation instead of telomere loss. These are exciting findings that provide food for thought about the role of telomeres and telomerase in hematopoietic stem cells.The role of telomerase in hematopoietic stem cells has been puzzling ever since the first reports of . . .
Case 35-2006: A Newborn Boy with Hypotonia
Authors: Nils Thomas Songstad, Claus Klingenberg, Per Ivar Kaaresen
Journal: New England Journal of Medicine (2007)

n engl j med 356;8 www.nejm.org february 22, 2007 874 neous migration of the parasite.1 In our patient, the nodule shifted early on in his hospitalization and became much less distinct. Therefore, although it was considered, a biopsy was not performed because it was thought to be of low diagnostic yield at the time. Kathryn B. Robertson, M.D. University of Colorado Health Sciences Center Denver, CO 80262 kathryn.robertson@uchsc.edu
Meckel's Diverticulum in Childhood
Authors: F A McPARLAND, W B KIESEWETTER
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Drug use and life style among college undergraduates in 1989: a comparison with 1969 and 1978
Authors: H G Pope, M Ionescu-Pioggia, H G Aizley, D K Varma
Journal: American Journal of Psychiatry (1990)

The authors conducted anonymous questionnaire studies of drug use and life style among college seniors at the same institution in 1969, 1978, and 1989. The 1989 group of students reported strikingly lower frequencies of virtually all forms of drug use than their counterparts in 1969 and 1978. As in 1969 and 1978, the drug users among the 1989 group were indistinguishable from nonusers in grades, athletic activities, other college activities, and feelings of alienation. Only visits to a psychiatrist and sexual activity distinguished users from nonusers.
Characteristics Of Multiple Myeloma Patients With 6-Year Or Longer Progression-Free Survival After a Single Autologous Transplant
Authors: Kehinde U.A. Adekola, Qaiser Bashir, Nina Shah, Sai Ravi Pingali, Simrit Parmar, Uday R Popat, Chitra M. Hosing, Richard E Champlin, Muzaffar H. Qazilbash
Journal: Blood (2013)